A history of Johnson & JohnsonSet up by three brothers back in 1886, Johnson & Johnson continues to keep evolving Share XA history of Johnson & Johnsonhttps://pharmaphorum.com/views-analysis-sales-marketing/a-history-of-johnson-johnson/
Ring 20: Could the rare disease get left behind by next-generation gene sequencing?Ring Chromosome 20 Syndrome, or (R)20, is an ultra-rare form of epilepsy with a devastating impact – yet Share XRing 20: Could the rare disease get left behind by next-generation gene sequencing?https://pharmaphorum.com/views-analysis-patients/ring-20-could-the-rare-disease-get-left-behind-by-next-generation-gene-sequencing/
Pfizer’s Revatio flunks paediatric hypertension studyAn attempt by Pfizer to extend the uses of its pulmonary artery hypertension (PAH) drug Revatio into a Share XPfizer’s Revatio flunks paediatric hypertension studyhttps://pharmaphorum.com/news/pfizers-revatio-flunks-paediatric-hypertension-study/
R&D Roundup: Pharma gets in on the biotech boomSome good news for the UK industry in turbulent times is always welcome, and several announcement this month Share XR&D Roundup: Pharma gets in on the biotech boomhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-pharma-gets-in-on-the-biotech-boom/
Merck & Co pens $340m pain drug deal with KCL and WellcomeMerck & Co has announced a deal with King’s College London (KCL) and Wellcome to investigate a new Share XMerck & Co pens $340m pain drug deal with KCL and Wellcomehttps://pharmaphorum.com/news/merck-co-pens-340m-pain-drug-deal-with-kcl-and-wellcome/
Brexit could disrupt medicine supplies for six months – ministerA no-deal Brexit could disrupt medicines supplies to the UK for at least six months because of delays Share XBrexit could disrupt medicine supplies for six months – ministerhttps://pharmaphorum.com/news/brexit-could-disrupt-medicine-supplies-for-six-months-minister/
What will a no-deal Brexit mean for pharma and healthcare?Britons are bracing themselves for the UK’s imminent departure from the European Union. A worst-case scenario would see Share XWhat will a no-deal Brexit mean for pharma and healthcare?https://pharmaphorum.com/views-and-analysis/what-will-a-no-deal-brexit-mean-for-pharma-and-healthcare/
EMA set for official move from London on 1 MarchThe European Medicines Agency (EMA) has officially taken over its new building in Amsterdam in preparation of its Share XEMA set for official move from London on 1 Marchhttps://pharmaphorum.com/news/ema-set-official-move-london/
Brexit and beyond: the challenges ahead for pharmaBrexit, and the political fallout from approving any deal, will continue to dominate British politics in 2019. It Share XBrexit and beyond: the challenges ahead for pharmahttps://pharmaphorum.com/views-analysis-sales-marketing/brexit-challenges-ahead-pharma/